Juan A. Cámara

This study shows that affinity-matured CD72-targeting nanobody CAR T-cells improve in vitro efficacy against CD72-low tumors but show limited in vivo benefit, while CD72 expression remains stable after CD19 resistance in B-cell malignancies.

This study shows that Eed is essential for craniofacial osteoblast differentiation and mesenchymal proliferation in neural crest cells, identified through mouse genetics, single-cell RNA sequencing, and epigenetic profiling.

This study shows that activating the STING pathway in osteosarcoma leads to tumor regression and immune memory, suggesting it as a therapeutic target.

This paper develops dual-antigen targeting CAR-T cells against CD70 and active integrin β2 to overcome AML antigen heterogeneity and reduce off-tumor toxicity.

This paper engineers T cells with synthetic receptors that activate only in the lung, demonstrating RAGE as a lung-specific target for targeted therapies.

Structure-optimized CD27-based CAR-T cells targeting CD70 show >80-fold improved expansion in vivo and offer a potential therapy for high-risk multiple myeloma patients.

The paper uses chemoproteomics to identify immunogenic cell surface substrates of CK2α in the tumor microenvironment, showing that extracellular phosphorylation can generate immunogenic antigens.